Greer Capital Advisors

ViroXis is a bio-pharmaceutical company focused on developing and commercializing innovative, properietary, botanical pharmaceuticals derived from Sandalwood Oil. The hardwood oils of the East Indian and West Australian sandalwood trees, S.album and S. spicatum, have a long and extensive history of traditional use for a variety of conditions, including the successful treatment of various skin disorders, including skin viral and difficult-to-treat microbial infections.

PNP Therapeutics, Inc. is a biopharmaceutical company based in Birmingham, Alabama, focused on developing innovative treatments for cancer. Established in 2000, the company utilizes a platform technology centered around a patented enzyme derived from E. coli purine nucleoside phosphorylase. This enzyme works with various nucleoside prodrugs to produce active metabolites that exhibit significant anti-tumor activity. PNP Therapeutics aims to enhance cancer treatment by providing nucleoside prodrugs that directly target and destroy tumor cells, thereby improving the overall effectiveness of cancer therapies for patients.

TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technology platforms to enrich its product discovery and development pipeline. Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms. The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama. TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively.